<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT943-11541</title>
	</head>
	<body>
		<main>
			<p>940729 FT  29 JUL 94 / UK Company News: Glaxo makes a further biotechnology link-up in US Glaxo, the drugs group, yesterday announced its 13th collaborative deal with a biotechnology company. Its latest partner is Sequana Therapeutics of La Jolla, California. The two companies will work in the genetics of diabetes field; it is unlikely to lead to any products until the next decade. The deal comes only five weeks after Glaxo signed its last biotechnology collaboration, also genetics, with Spectra Biomedical, the northern California migraine specialist. Under the latest deal, Glaxo gains exclusive rights to develop and market drugs, while Sequana keeps the rights to any diagnostics products that might emerge. Glaxo will pay an up-front fee to Sequana and further cash payments as research progresses. It will also offer research support.</p>
		</main>
</body></html>
            